Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Bataller A, et al. Among authors: hammond d. Lancet Haematol. 2024 Mar;11(3):e186-e195. doi: 10.1016/S2352-3026(23)00367-8. Epub 2024 Feb 2. Lancet Haematol. 2024. PMID: 38316133 Clinical Trial.
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: hammond d. Am J Hematol. 2021 Feb 1;96(2):E50-E53. doi: 10.1002/ajh.26044. Epub 2020 Nov 21. Am J Hematol. 2021. PMID: 33156969 Free article. No abstract available.
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: hammond d. Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12. Leukemia. 2021. PMID: 33846541 No abstract available.
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. DiNardo CD, et al. Among authors: hammond d. Blood Adv. 2023 Jun 13;7(11):2378-2387. doi: 10.1182/bloodadvances.2022008378. Blood Adv. 2023. PMID: 35973199 Free PMC article.
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Abbas HA, et al. Among authors: hammond d. Leuk Lymphoma. 2022 Dec;63(13):3105-3116. doi: 10.1080/10428194.2022.2118533. Epub 2022 Sep 10. Leuk Lymphoma. 2022. PMID: 36089905 Free PMC article.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bazinet A, et al. Among authors: hammond d. Cancer. 2023 Feb 15;129(4):560-568. doi: 10.1002/cncr.34564. Epub 2022 Dec 2. Cancer. 2023. PMID: 36458426 Free article.
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Siddiqui M, et al. Among authors: hammond d. Am J Hematol. 2023 Apr;98(4):E91-E94. doi: 10.1002/ajh.26858. Epub 2023 Feb 1. Am J Hematol. 2023. PMID: 36661399 Free article. No abstract available.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Richard-Carpentier G, et al. Among authors: hammond d. Haematologica. 2023 Sep 1;108(9):2331-2342. doi: 10.3324/haematol.2022.282030. Haematologica. 2023. PMID: 36951163 Free PMC article.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: hammond de. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846 Free article.
1,594 results